Why Myra Ahmad Believes Longevity Medicine Needs a Physician

The Longevity Category Nobody Regulates

Longevity medicine has become one of the fastest-growing corners of consumer health. It covers everything from hormone optimization to peptide therapy to skincare marketed on its ability to extend healthy years rather than just treat a diagnosis.

Much of that market operates with almost no physician involvement at all. A patient can order peptides, supplements, or hormone products from a wellness brand, a supplement shop, or an unregulated online seller, and self-administer a protocol assembled from social media rather than a clinician who actually knows their medical history.

Myra Ahmad, the founder and CEO of Mochi Health, has built her company’s longevity offering on the opposite premise.

Mochi Health lists longevity among its treatment categories, delivered the same way the rest of its platform operates: through a licensed physician who reviews a patient’s history and prescribes accordingly, rather than a self-directed purchase.

What Myra Ahmad’s Background Brings to This Argument

Ahmad’s position on longevity care is shaped directly by her own clinical training. She earned her MD from the University of Washington School of Medicine and conducted research at MIT and UCSF before founding Mochi Health in 2022.

That background has been an enormous influence on her career. Longevity medicine sits at the intersection of several disciplines. Endocrinology, dermatology, metabolic health. A general wellness brand has no obligation to understand these concepts deeply.

A patient taking a peptide for one purpose and a hormone product for another, without a single clinician reviewing both, is assembling a protocol with no one checking for interactions.

That is the structural gap Ahmad has pointed to in describing why she has been drawn to longevity as a category worth building into a physician led platform rather than leaving it to the unregulated wellness market.

The Case Against Self-Directed Protocols

The biohacking approach to longevity has real appeal. It is fast, it does not require an appointment, and it lets a patient experiment on their own timeline.

It also removes the one safeguard that matters most in a category built around hormones and peptides, substances that can meaningfully affect a body’s systems and that carry real risk when dosed incorrectly or combined without clinical oversight.

An unsupervised protocol also has no mechanism for catching a problem early. A physician managing a patient’s longevity plan can order labs, track how a patient’s markers respond over time, and adjust a plan based on actual data.

A patient assembling their own protocol from products bought separately has none of that feedback loop, which means a problem typically surfaces only after it has already become one.

Why Health Span, Not Just Weight, Is the Framing

Longevity medicine is meant to be broader than weight management alone. It covers hormone-related care, skincare tied to long-term skin health rather than cosmetic result alone, and the general goal of extending the years a person spends in good health, not just the years they are alive.

That framing treats longevity as a clinical specialty in its own right, with its own body of evidence and its own set of judgment calls.

A platform that treats longevity this way has to staff it accordingly.

Mochi Health’s approach has been to route the category through the same physician-guided structure it uses for its other treatment areas, on the theory that the clinical judgment required to manage hormone therapy or peptide use safely is not fundamentally different from the judgment required to manage a GLP-1 prescription responsibly, even though the specific medical questions differ.

What This Means for a Patient Considering Longevity Care

For a patient curious about longevity medicine, the practical choice is between two very different starting points: a self-directed protocol assembled from products bought independently, or a physician-reviewed plan built around that patient’s actual labs and history.

The first path is faster and requires no appointment. The second path is slower by design, because it involves an actual clinical evaluation before anything is prescribed.

Ahmad’s argument is that the slower path is the correct one for a category involving hormones, peptides, and long-term health outcomes.

A physician who can order labs, track a patient’s response, and adjust a plan accordingly is positioned to catch problems a self-administered protocol has no way of catching.

The Cost of Getting This Wrong

The stakes in longevity medicine are easy to underestimate precisely because the category markets itself around wellness rather than illness. A patient is not typically being treated for a diagnosed condition when they start a longevity protocol. They are trying to feel better, look better, or extend a healthy stretch of life further than it might otherwise go, which can make the whole category feel lower stakes than it actually is.

That framing is misleading. Hormone therapy carries real physiological effects that need monitoring over time, and peptides, many of which are still being studied for long-term safety, are not risk-free simply because they are marketed as natural or restorative.

A physician managing a longevity plan is not adding unnecessary friction to a wellness purchase. They are applying the same clinical standard to hormones and peptides that any other prescription drug would require, which is precisely the standard a large share of the unregulated longevity market currently skips.

A Standard Worth Holding the Category To

None of this means longevity medicine has to move slowly forever, or that physician oversight has to feel like a barrier between a patient and the care they want. It means the oversight has to actually be there, built into the platform rather than treated as optional.

That is the standard Ahmad has applied to Mochi Health’s own longevity category, and it is the standard she has argued the broader industry should be judged against as more companies rush to capture a fast growing market with far less clinical infrastructure behind it.